Current Controlled Trials - Search the ISRCTN Register of Clinical Trials.

Welcome

02 September 2010

	Trial registration
	Unique identification scheme
	International databases

Find trials

ISRCTN Register

Registration

New application

Updating record

Information

introduction

governing board

ISRCTN FAQs

data set

guidance notes

International Standard Randomised Controlled Trial Number Register

Showing records: 8281 to 8290 of 9074

SEARCH FOR	RESULTS ORDER	DIRECTION	MAX RESULTS

8281	The effect of a lutein based nutritional supplement on non-exudative age-related macular degeneration (AMD): a double-masked randomised controlled trial
	ISRCTN:	ISRCTN78467674
	Sponsor:	Aston University (UK)
	Date assigned:	11 September 2003

8282	A partially-blind phase III randomised trial of fulvestrant (Faslodex™) with or without concomitant anastrozole (Arimidex™) compared with exemestane in post-menopausal women with oestrogen receptor (ER) positive locally advanced/metastatic breast cancer following progression on non-steroidal aromatase inhibitors
	ISRCTN:	ISRCTN44195747
	Sponsor:	Sponsor not defined - Record supplied by Institute of Cancer Research (UK)
	Date assigned:	08 September 2003

8283	The Vasopressin in Pediatric Vasodilatory Shock Trial
	ISRCTN:	ISRCTN11597444
	Sponsor:	Children�s Hospital of Eastern Ontario Research Institute (CHEORI) (Canada)
	Date assigned:	08 September 2003

8284	Intensive Scheduled Management strategy for improving blood pressure control in patients in primary care
	ISRCTN:	ISRCTN05874865
	Sponsor:	The Heart and Stroke Foundation of Ontario (Canada)
	Date assigned:	08 September 2003

8285	Home Blood Pressure Monitoring and blood pressure (BP) control
	ISRCTN:	ISRCTN25105161
	Sponsor:	Heart and Stroke Foundation of Ontario (Canada)
	Date assigned:	08 September 2003

8286	A randomised, multicentre, open label, phase Il study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease (SCD) patients with transfusional haemosiderosis
	ISRCTN:	ISRCTN05896089
	Sponsor:	Novartis Pharmaceuticals Corporation (USA)
	Date assigned:	05 September 2003

8287	A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in β-thalassaemia patients with transfusional haemosiderosis
	ISRCTN:	ISRCTN93355192
	Sponsor:	Novartis Pharmaceuticals Corporation (USA)
	Date assigned:	05 September 2003

8288	An evaluation of Motivational (MI) plus Cognitive Therapy (CBT) for Schizophrenia and Substance Misuse
	ISRCTN:	ISRCTN14404480
	Sponsor:	University of Manchester (UK)
	Date assigned:	01 September 2003

8289	The Sherbrooke Model
	ISRCTN:	ISRCTN60233560
	Sponsor:	The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)
	Date assigned:	22 August 2003

8290	Does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk localised breast cancer?
	ISRCTN:	ISRCTN79831382
	Sponsor:	The University of Sheffield (UK)
	Date assigned:	20 August 2003

RESULT PAGE

829


© 2010 ISRCTN unless otherwise stated.